Is it safe?
Can HALO take a bad year?
Halozyme Therapeutics, Inc. carries $1.83B of net debt at 3.50× EBITDA: a load its earnings can carry.
$1.83B
Net debt · as at Q1 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 3.50×
Net debt / EBITDA · 2.19× a year ago · the load is going up
- Altman Z-score
- 3.59
Altman Z-score · safe zone, above 3
- Interest cover
- 26.8×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ1 2026
- $2.14B
- Cash and short-term investments
- $310M
- Net debt
- $1.83B
- EBITDA, trailing twelve months
- $525M
- Operating profit, trailing twelve months
- $512M
- Debt / equity
- 9.77×
- Total debt / EBITDA
- 4.09×
- Annualised volatilitytwo years of daily moves
- 44%
- Worst drawdown on file
- −49%
- Below its 52-week high
- −2.1%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.